The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH.